Could He Jiankui have faked part or all of his CRISPR babies story? If so, how? Why? Or to put it another way, almost everyone seems to be assuming the story is real, but should we be more skeptical? Should we flip things around and assume the story isn’t entirely kosher until proven otherwise? I once […]
History tells us to be more skeptical of He Jiankui’s CRISPR baby story Read More »
In Parkinson’s Disease patients develop neurological dysfunction as they lose a special kind of brain cell called dopaminergic (or dopamine) neurons. While a number of different approaches to this disease have been studied for decades, nothing has proven particularly successful in slowing its progression. As a result there has been a big need for novel thinking
Hope on Parkinson’s front: Japan IPSC trial 1st patient Read More »
The stem cell clinic industry selling unapproved “therapies” is ubiquitous and yet somehow still growing it seems. Many of us are encountering more of them including via ads and the clinics are basically all over the place. What should someone do if they see or have had a bad experience with a stem cell clinic
Report a bad clinic Read More »
Magenta Therapeutics is a biotech company with a portfolio including stem cell products. Their most well known investigational drug product is an expanded umbilical cord stem cell product called MGTA-456, an “ex-Novartis” product. Magenta just released new trial data on MGTA-456, which I see as a case of good news-bad news, and investors seem to
Magenta Therapeutics Good News-Bad News Trial Data Read More »
Remember when the Piero Anversa situation first made news or at least when you first heard about it? In the public domain, it was back around April 2014. I didn’t even do a whole post on it, but rather it made two bullet points in a post about a set of bad overall news including the latest
Anversa debacle vs. STAP cell train wreck & what’s next Read More »
There’s a new paper in Cell Stem Cell on esophageal organoids that has really caught people’s attention. It is entitled, “3D Modeling of Esophageal Development using Human PSC-Derived Basal Progenitors Reveals a Critical Role for Notch Signaling.” It comes from a team led by Jianwen Que. Update: I didn’t realize when I first did this post that
Digesting new esophageal organoids papers Read More »
What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on
ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »
What the devil is a vampire facial? I first heard about the vampire facial, sometimes also called a “vampire facelift” when professional celebrity Kim Kardashian reportedly got one. I weighed in on that five years ago here. There was some question in how this procedure was portrayed as to whether it involved stem cells, which
Vampire facial update: Kardashian has regrets, others maybe infections Read More »
Time to sell exosome therapies to patients? No. Some stem cell clinics and related firms are looking for new ways to make profits and toward that goal a few have latched onto the legitimate buzz around exosome research. What are exosomes? Imagine if you could bubble up a pea-sized sphere off your skin full of
As exosome work advances, clinics pitch unproven therapies to patients Read More »
It’s an odd confluence of events this week that (A) the Nuffield Council, an ethics think tank, gives a thumbs up in a new report to heritable human genetic modification that would probably include using CRISPR in the same week that (B) a new paper reports that CRISPR can cause unpredictable genomic damage and several other concerning reports
Mixed Nuffield Council Report Too Aspirational on Human Genetic Modification Read More »